Adamis Pharmaceuticals Corp (NASDAQ:ADMP) has been assigned a consensus broker rating score of 1.50 (Buy) from the two brokers that cover the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a buy rating and one has issued a strong buy rating on the company.

Brokerages have set a twelve-month consensus target price of $9.83 for the company and are predicting that the company will post ($0.16) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Adamis Pharmaceuticals an industry rank of 104 out of 265 based on the ratings given to related companies.

ADMP has been the subject of a number of research reports. B. Riley reaffirmed a “buy” rating and set a $9.50 price target on shares of Adamis Pharmaceuticals in a research report on Wednesday, October 4th. Zacks Investment Research cut shares of Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, November 20th. ValuEngine cut shares of Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, October 3rd. Maxim Group reaffirmed a “buy” rating and set a $13.00 price target on shares of Adamis Pharmaceuticals in a research report on Monday, August 21st. Finally, Raymond James Financial began coverage on shares of Adamis Pharmaceuticals in a report on Tuesday, September 12th. They issued an “outperform” rating and a $7.00 price objective on the stock.

Shares of Adamis Pharmaceuticals (NASDAQ ADMP) traded down $0.05 during trading on Tuesday, reaching $4.00. 689,000 shares of the company were exchanged, compared to its average volume of 730,169. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.93 and a quick ratio of 3.79. Adamis Pharmaceuticals has a 12-month low of $2.55 and a 12-month high of $6.45.

A number of hedge funds have recently modified their holdings of the business. Northern Trust Corp lifted its holdings in Adamis Pharmaceuticals by 5.5% in the 2nd quarter. Northern Trust Corp now owns 51,108 shares of the specialty pharmaceutical company’s stock worth $266,000 after buying an additional 2,686 shares in the last quarter. Stonebridge Capital Advisors LLC raised its stake in shares of Adamis Pharmaceuticals by 22.2% in the 2nd quarter. Stonebridge Capital Advisors LLC now owns 27,500 shares of the specialty pharmaceutical company’s stock valued at $143,000 after purchasing an additional 5,000 shares in the last quarter. Leisure Capital Management raised its stake in shares of Adamis Pharmaceuticals by 7.2% in the 2nd quarter. Leisure Capital Management now owns 145,909 shares of the specialty pharmaceutical company’s stock valued at $759,000 after purchasing an additional 9,832 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of Adamis Pharmaceuticals by 131.0% in the 3rd quarter. Bank of New York Mellon Corp now owns 27,464 shares of the specialty pharmaceutical company’s stock valued at $143,000 after purchasing an additional 15,577 shares in the last quarter. Finally, Virtu KCG Holdings LLC raised its stake in shares of Adamis Pharmaceuticals by 103.2% in the 2nd quarter. Virtu KCG Holdings LLC now owns 38,474 shares of the specialty pharmaceutical company’s stock valued at $200,000 after purchasing an additional 19,538 shares in the last quarter. Hedge funds and other institutional investors own 16.73% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was originally published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/05/adamis-pharmaceuticals-corp-admp-given-9-83-average-target-price-by-analysts.html.

About Adamis Pharmaceuticals

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).

Get a free copy of the Zacks research report on Adamis Pharmaceuticals (ADMP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Adamis Pharmaceuticals Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals Corp and related companies with MarketBeat.com's FREE daily email newsletter.